After 48 h, NKG2D-CD3 was found to induce superior leukemia cell killing compared to the NK cell activating constructs with NKG2D-CD16 still mediating profoundly stronger effects than NKG2D-Fc-ADCC (Fig. 4c). Here, FCGR3B is linked to leukemia.